<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550510</url>
  </required_header>
  <id_info>
    <org_study_id>11D.459</org_study_id>
    <nct_id>NCT01550510</nct_id>
  </id_info>
  <brief_title>Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA</brief_title>
  <official_title>Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment
      with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced
      colorectal cancer who have failed at least one treatment regimen with a 5-FU based therapy.
      This study will be conducted as an amendment to Investigational New Drug # 77486.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: To assess whether or not (IV) Ascorbic Acid (AA) with irinotecan therapy is
      relatively safe and well-tolerated. This aim will be assessed by enrolling a minimum of 6
      subjects meeting inclusion criteria, using a modified 3+3 design. Safety will be assessed
      with the following: toxicity graded by the NCI CTC, urinalysis pre- and post-infusion, basic
      metabolic panel, and CBC. From our experience and in the experience of our study
      collaborators, we hypothesize that the combination of IV AA with irinotecan will not be
      associated with adverse events.

      Phase II: To utilize CT or PET/CT (when available) scans to evaluate disease progression to
      assess overall tumor response rate (complete and partial response) in subjects with advanced
      or recurrent colorectal cancer treated with the combination of ascorbic acid and irinotecan
      versus irinotecan alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed: low enrollment, many treatment options available for Colorectal Cancer
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</measure>
    <time_frame>9 weeks +/- 2 weeks</time_frame>
    <description>Safety: The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with irinotecan therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Are Alive After 11 Weeks.</measure>
    <time_frame>9 weeks +/- 2 weeks</time_frame>
    <description>To evaluate progression-free survival related to treatment of patients with advanced or recurrent colorectal cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Stage IV Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Ascorbic Acid + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (irinotecan alone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>350mg/m2 irinotecan once a week every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>3x a week for 9 weeks</description>
    <arm_group_label>Ascorbic Acid + Irinotecan</arm_group_label>
    <other_name>Ascorbate</other_name>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>350mg/m2 once a week every 3 weeks</description>
    <arm_group_label>Ascorbic Acid + Irinotecan</arm_group_label>
    <arm_group_label>Standard of Care (irinotecan alone)</arm_group_label>
    <other_name>Camptothecin-11</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Metastatic colorectal carcinoma (stage IV disease).

          -  Patients must have progressed on one or more prior chemotherapy treatment regimens
             including at least one trial of a 5-FU/oxaliplatin based therapy (FOLFOX) in
             combination with bevacizumab. Patients must not have had standard chemotherapy within
             at least 2 weeks of beginning ascorbic acid treatment provided that they have
             recovered from any toxicities that they experienced.

          -  G6PD status &gt; lower limit of normal

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper
             limit (if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine
             clearance will be obtained); transaminase (AST/ALT) ≤2.0X upper limit of normal;
             bilirubin levels ≥ 2 mg/dL; ANC ≥1,500/mm3; Hemoglobin &gt; 8g/dL; platelet ≥
             100,000/mm3;

          -  Women of childbearing potential will confirm a negative pregnancy test and must
             practice effective contraception during the study.

          -  Willing and able to provide informed consent and participate in the study procedures.

        Exclusion Criteria:

          -  Patients with evidence of a significant current psychiatric disorder that would
             prevent completion of the study as determined by the PI will not be allowed to
             participate.

          -  Co-morbid medical condition that would affect survival or tolerance as determined by
             the PI. This includes patients who have not fully recovered from toxicities associated
             with prior therapy. It also includes subjects who, as determined by the PI, are at
             risk of experiencing fluid overload (i.e., congestive heart failure).

          -  Patients who currently abuse alcohol or drugs.

          -  Patients with known glomerular filtration rate of &lt;60ml/min or with nephrotic range
             proteinuria.

          -  Pregnant or lactating women

          -  Enrollment in active clinical trial/ experimental therapy or IND study within the
             prior 30 days.

          -  Contraindication for CT or PET/CT as per the PI.

          -  Patients who are on strong inducers of CYP3A4 which include but are not limited to:
             Aminoglutethimide, Bexarotene, Bosentan, Carbamazepine, Dexamethasone, Efavirenz,
             Fosphenytoin, Griseofulvin, Modafinil, Nafcillin, Nevirapine, Oxcarbazepine,
             Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Rifapentine, St. John's
             wort.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Monti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>June 25, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2018</results_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IV Colorectal cancer</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamins</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Integrative Medicine</keyword>
  <keyword>Complementary Medicine</keyword>
  <keyword>Alternative Medicine Antioxidants</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Protective Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Growth Substances</keyword>
  <keyword>Antineoplastic Agents, Phytogenic</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Radiation-Sensitizing Agents</keyword>
  <keyword>Topoisomerase I Inhibitors</keyword>
  <keyword>Topoisomerase Inhibitors</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ascorbic Acid</title>
          <description>Ascorbic Acid (50-100g, 3x weekly)
Ascorbic Acid: 3x a week for 9 weeks</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care (Irinotecan Alone)</title>
          <description>350mg/m2 once a week every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Phase 2 portion of this study never enrolled and therefore no patients were enrolled to the standard of care arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Ascorbic Acid+Irinotecan</title>
          <description>Ascorbic Acid (50-100g, 3x weekly)
Ascorbic Acid: 3x a week for 9 weeks</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care (Irinotecan Alone)</title>
          <description>350mg/m2 once a week every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</title>
        <description>Safety: The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with irinotecan therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</description>
        <time_frame>9 weeks +/- 2 weeks</time_frame>
        <population>The study was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid+Irinotecan</title>
            <description>Ascorbic Acid (50-100g, 3x weekly)
Ascorbic Acid: 3x a week for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Irinotecan Alone)</title>
            <description>350mg/m2 once a week every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</title>
          <description>Safety: The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with irinotecan therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</description>
          <population>The study was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Are Alive After 11 Weeks.</title>
        <description>To evaluate progression-free survival related to treatment of patients with advanced or recurrent colorectal cancer</description>
        <time_frame>9 weeks +/- 2 weeks</time_frame>
        <population>The study was closed early due to lack of accrual. The data were not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid</title>
            <description>Ascorbic Acid (50-100g, 3x weekly)
Ascorbic Acid: 3x a week for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Irinotecan Alone)</title>
            <description>350mg/m2 once a week every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Are Alive After 11 Weeks.</title>
          <description>To evaluate progression-free survival related to treatment of patients with advanced or recurrent colorectal cancer</description>
          <population>The study was closed early due to lack of accrual. The data were not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The study was closed early due to lack of accrual. Adverse event data were collected for the patients who were enrolled in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ascorbic Acid+Irinotecan</title>
          <description>Ascorbic Acid (50-100g, 3x weekly)
Ascorbic Acid: 3x a week for 9 weeks</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care (Irinotecan Alone)</title>
          <description>350mg/m2 once a week every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Monti</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215 955-2221</phone>
      <email>daniel.monti@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

